Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
1.
J Vet Cardiol ; 18(4): 310-325, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27613648

ABSTRACT

INTRODUCTION: To investigate the pharmacokinetics and pharmacodynamics of oral pimobendan in conscious, healthy cats. ANIMALS: Eight healthy adult cats. MATERIALS AND METHODS: A randomised, single-blinded, crossover design was used. Two oral doses of pimobendan (0.625-mg [LD], 1.25-mg [HD]) and a control substance (3-mL water) were administered to each cat. Blood collection, echocardiography, and oscillometric blood pressure measurements were performed repeatedly for 12 h following each dose. Plasma concentrations of pimobendan and the active metabolite, O-desmethylpimobendan (ODMP), were quantified using ultra-high-performance liquid chromatography tandem mass spectrometry. Cardiovascular parameters were evaluated for between- and within-treatment effects over time using linear mixed modelling. RESULTS: Pimobendan was rapidly absorbed and converted to ODMP with the pimobendan AUC0-∞ greater than ODMP AUC0-∞ (ODMP:pimobendan AUC0-∞ ratio 0.6 [LD] and 0.5 [HD]) despite a longer elimination half-life of ODMP (pimobendan t1/2 0.8 h vs. ODMP t1/2 1.6 h [LD]; pimobendan t1/2 0.7 h vs. ODMP t1/2 1.3 h [HD]). Averaged across all time points, pimobendan increased several measures of systolic function; however, its effect could not be further characterised. Although treatment was well-tolerated, two cats vomited following HD and another had a ventricular premature beat recorded following LD. CONCLUSIONS: The lower ODMP:pimobendan AUC0-∞ ratio compared to that observed previously in dogs suggests reduced metabolism in cats. Treatment effects were observed in measures of systolic function; however, the duration of action and differences in effects between the two pimobendan doses could not be characterised. Further studies are required to evaluate pimobendan in feline cardiovascular medicine.


Subject(s)
Cardiotonic Agents/pharmacokinetics , Cardiovascular System/drug effects , Cats , Pyridazines/pharmacokinetics , Administration, Oral , Animals , Blood Pressure/drug effects , Cardiotonic Agents/pharmacology , Cross-Over Studies , Echocardiography/veterinary , Female , Male , Observer Variation , Pyridazines/adverse effects , Pyridazines/metabolism , Pyridazines/pharmacology , Single-Blind Method
2.
J Vet Pharmacol Ther ; 39(1): 45-53, 2016 Feb.
Article in English | MEDLINE | ID: mdl-25997373

ABSTRACT

Pimobendan is an inodilator used in the treatment of canine congestive heart failure (CHF). The aim of this study was to investigate the pharmacokinetics and cardiovascular effects of a nonaqueous oral solution of pimobendan using a single-dose, operator-blinded, parallel-dose study design. Eight healthy dogs were divided into two treatment groups consisting of water (negative control) and pimobendan solution. Plasma samples and noninvasive measures of cardiovascular function were obtained over a 24-h period following dosing. Pimobendan and its active metabolite were quantified using an ultra-high-performance liquid chromatography-mass spectrometer (UHPLC-MS) assay. The oral pimobendan solution was rapidly absorbed [time taken to reach maximum concentration (Tmax ) 1.1 h] and readily converted to the active metabolite (metabolite Tmax 1.3 h). The elimination half-life was short for both pimobendan and its active metabolite (0.9 and 1.6 h, respectively). Maximal cardiovascular effects occurred at 2-4 h after a single oral dose, with measurable effects occurring primarily in echocardiographic indices of systolic function. Significant effects persisted for <8 h. The pimobendan nonaqueous oral solution was well tolerated by study dogs.


Subject(s)
Pyridazines/pharmacokinetics , Vasodilator Agents/pharmacokinetics , Administration, Oral , Animals , Area Under Curve , Dogs , Female , Half-Life , Male , Pyridazines/administration & dosage , Vasodilator Agents/administration & dosage
3.
J Clin Pharm Ther ; 39(5): 555-60, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25040563

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: A common polymorphism (C1858T) in the gene that encodes the protein tyrosine phosphatase non-receptor type 22 (PTPN22) is associated with altered T-cell responses and increased susceptibility to rheumatoid arthritis (RA) and other autoimmune diseases. Teriflunomide, the active metabolite of leflunomide, reduces T-cell responses through inhibition of tyrosine kinase p56LCK. We examined a potential association between PTPN22 genotype and response or toxicity to leflunomide in Caucasian RA patients taking leflunomide in combination with other disease-modifying antirheumatic drugs (DMARDs). METHODS: Patients enrolled in the Royal Adelaide Hospital RA inception cohort and taking leflunomide were eligible for inclusion. Participants were followed for 12 months after leflunomide initiation or until either another DMARD was added or leflunomide was ceased. Clinical response according to change in 28-joint Disease Activity Score (DAS28) and cessation due to toxicity were assessed. RESULTS AND DISCUSSION: A total of 94 participants were included in the study, 75 of whom carried the CC genotype, 18 the CT, whereas one individual carried the TT genotype. Over the first 12 months of leflunomide treatment, there was no statistically significant relationship between carrying the T allele and change in DAS28 (-0·84 vs. -1·15, P = 0·446) nor with cessation of leflunomide treatment due to side effects (P = 0·433). These results indicate that PTPN22 C1858T genotype has no effect on response or toxicity outcomes in leflunomide-treated RA patients. WHAT IS NEW AND CONCLUSION: This is the first study to evaluate the biologically plausible hypothesis that PTPN22 genotype might be a predictor of response/toxicity to leflunomide therapy. Despite this, PTPN22 genotype was not associated with leflunomide response or toxicity in patients with RA.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Arthritis, Rheumatoid/genetics , Genetic Predisposition to Disease , Isoxazoles/therapeutic use , Polymorphism, Genetic , Protein Tyrosine Phosphatase, Non-Receptor Type 22/genetics , Adjuvants, Immunologic/toxicity , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/drug therapy , Female , Humans , Isoxazoles/toxicity , Leflunomide , Male , Middle Aged , Proportional Hazards Models , South Australia , Treatment Outcome , White People/genetics
4.
Aust Vet J ; 87(9): 349-51, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19703134

ABSTRACT

Between June 2008 and March 2009, 87 cats in Australia developed symmetrical hindlimb ataxia, paraparesis, tetraparesis, paraplegia or tetraplegia in association with eating an imported, irradiated dry pet food. This communication reports the clinical signs and outcomes of those cats.


Subject(s)
Animal Feed/adverse effects , Animal Feed/radiation effects , Cat Diseases/etiology , Food Irradiation/adverse effects , Paresis/veterinary , Animals , Cat Diseases/mortality , Cat Diseases/pathology , Cats , Female , Gamma Rays , Male , Paresis/etiology , Paresis/mortality , Paresis/pathology
5.
J Evol Biol ; 21(1): 263-275, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18021202

ABSTRACT

Beak size and shape in Darwin's finches have traditionally been quantified using a few univariate measurements (length, depth, width). Here we show the improved inferential resolution of geometric morphometric methods, as applied to three hierarchical levels: (i) among seven species on Santa Cruz Island, (ii) among different sites on Santa Cruz for a single species (Geospiza fortis), and (iii) between large and small beak size morphs of G. fortis at one site (El Garrapatero). Our results support previous studies in finding an axis of shape variation (long/shallow/pointy vs. short/deep/blunt) that separates many of the species. We also detect additional differences among species in the relative sizes and positions of the upper and lower mandibles and in curvature of the mandibles. Small-scale, but potentially relevant, shape variation was also detected among G. fortis from different sites and between sympatric beak size morphs. These results suggest that adaptation to different resources might contribute to diversification on a single island.


Subject(s)
Beak/anatomy & histology , Biometry/methods , Finches/anatomy & histology , Animals , Finches/genetics , Genetic Speciation , Genetic Variation
6.
Int J Clin Pharmacol Ther ; 45(7): 410-7, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17725248

ABSTRACT

OBJECTIVE: To investigate the influence of CYP2D6 genotype on the oral clearance of (R)-, (S)- and rac-methadone. METHODS: In this retrospective study, CYP2D6 genotypes were identified in 56 methadone maintained subjects. Plasma concentrations of (R)-, (S)- and rac-methadone were determined by stereoselective HPLC and sufficient data were available to estimate the apparent oral clearances of (R)-, (S)- and rac-methadone using a population kinetic model in 37 of the genotyped subjects. RESULTS: The CYP2D6 allele frequencies were similar to those previously reported in Caucasians, the most common being: CYP2D6*1 (35.2%), CYP2D6*2 (12.0%) and CYP2D6*4 (22.2%). Three unknown SNPs were found in four subjects: 1811G > A (n = 1), 1834C > T (n = 1) and 2720G > C (n = 2). The oral clearances of (R)-, (S)- and rac-methadone varied 5.4-, 6.8- and 6.1-fold, respectively. No significant differences in methadone oral clearance were found between CYP2D6 genotypic PM, IM and EM (p = 0.57, 0.40 and 0.43 for (R)-, (S)- and rac-methadone, respectively). Only 1 subject had duplication of functional CYP2D6 alleles and the oral clearance of the three analytes was not markedly altered. CONCLUSIONS: CYP2D6 poor, intermediate and extensive metabolizer genotypes did not appear to impact on the oral clearance of (R)-, (S)- or rac-methadone. In addition, methadone dosage requirements were not influenced by CYP2D6 genotypes in these subjects. However, the impact of duplication of functional CYP2D6 alleles on oral clearance and dosage requirements requires further investigation.


Subject(s)
Analgesics, Opioid/pharmacokinetics , Cytochrome P-450 CYP2D6/genetics , Methadone/pharmacokinetics , Adult , Alleles , Analgesics, Opioid/blood , Analgesics, Opioid/chemistry , Analgesics, Opioid/therapeutic use , Cytochrome P-450 CYP2D6/metabolism , Female , Genotype , Humans , Male , Methadone/blood , Methadone/chemistry , Methadone/therapeutic use , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/genetics , Opioid-Related Disorders/metabolism , Pain/drug therapy , Pain/genetics , Pain/metabolism , Phenotype , Pregnancy , Stereoisomerism
7.
Br J Pharmacol ; 149(6): 754-60, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17016501

ABSTRACT

BACKGROUND AND PURPOSE: At present there are few data regarding the rate and extent of brain-blood partitioning of the opioid active metabolite of morphine, morphine-6-glucuronide (M6G). In this study the cerebral kinetics of M6G were determined, after a short-term intravenous infusion, in chronically instrumented conscious sheep. EXPERIMENTAL APPROACH: Five sheep received an intravenous infusion of M6G 2.2 mg kg(-1) over a four-minute period. Non-linear mixed-effects analysis, with hybrid physiologically based kinetic models, was used to estimate cerebral kinetics from the arterio-sagittal sinus concentration gradients and cerebral blood flow measurements. KEY RESULTS: A membrane limited model was selected as the final model. The blood-brain equilibration of M6G was relatively slow (time to reach 50% equilibration of the deep compartment 5.8 min), with low membrane permeability (PS, population mean, 2.5 ml min(-1)) from the initial compartment (V1, 13.7 ml) to a small deep distribution volume (V2) of 18.4 ml. There was some between-animal variability (%CV) in the initial distribution volume (29%), but this was not identified for PS or V2. CONCLUSION AND IMPLICATIONS: Pharmacokinetic modelling of M6G showed a delayed equilibration between brain and blood of a nature that is primarily limited by permeability across the blood-brain-barrier, in accordance with its physico-chemical properties.


Subject(s)
Morphine Derivatives/pharmacokinetics , Animals , Blood-Brain Barrier , Chromatography, High Pressure Liquid , Morphine Derivatives/blood , Sheep
8.
Water Sci Technol ; 52(1-2): 67-72, 2005.
Article in English | MEDLINE | ID: mdl-16180410

ABSTRACT

Land application of wastewater biosolids is both economical and beneficial to resource recycling. However, this environmentally friendly practice can be at risk due to odor complaints. Volatile organic sulfur compounds (VOSCs) including methanethiol, dimethyl sulfide, and dimethyl disulfide, have been identified as major contributors to biosolids odor. In this study, methanogens were shown to play a key role in removing VOSCs and reducing odors, and methane production was related to reduced VOSC production. Factors influencing the growth of methanogens such as the shear during dewatering and storage temperature showed a strong impact on net odor production. Examination of the microbial communities of both bacteria and archaea indicated a simplified archaeal community in biosolids, which is susceptible to environmental perturbations. Therefore, one possible odor control strategy is the preservation and enhancement of the methanogenic population during biosolids storage.


Subject(s)
Bacteria, Anaerobic/metabolism , Euryarchaeota/metabolism , Odorants , Sewage/microbiology , Sulfhydryl Compounds/metabolism , Air Pollutants/metabolism , Bacteria, Anaerobic/genetics , DNA, Archaeal/analysis , DNA, Bacterial/analysis , Euryarchaeota/genetics , Methane/metabolism , Volatilization , Waste Disposal, Fluid
10.
J Feline Med Surg ; 7(2): 77-93, 2005 Apr.
Article in English | MEDLINE | ID: mdl-15771944

ABSTRACT

The medical records of 62 cats with clinical signs of central nervous system disease and accompanying inflammatory cerebrospinal fluid (CSF) analysis were examined retrospectively to determine if signalment, clinical signs, CSF analysis and ancillary testing could accurately predict the type of central nervous system disease that was present. An inflammatory CSF was defined as one in which a total nucleated cell count was greater than 5 cells/microl or one in which the total nucleated cell count was normal but the nucleated cell differential count was abnormal. Sex, degree of CSF inflammation, neuroanatomical location and systemic signs provided little contributory information to the final diagnosis. In 63% of the cases a presumptive diagnosis could be made based on a combination of clinical signs, clinicopathological data and ancillary diagnostic tests. CSF analysis alone was useful only in the diagnosis of cats with feline infectious peritonitis, Cryptococcus species infection, lymphoma and trauma. Overall, despite extensive diagnostic evaluation, a specific diagnosis could not be made in 37% of cats. The prognosis for cats with inflammatory CSF was poor with 77% of cats surviving less than 1 year.


Subject(s)
Cat Diseases/cerebrospinal fluid , Central Nervous System Diseases/veterinary , Encephalitis/veterinary , Animals , Cat Diseases/pathology , Cats , Central Nervous System Diseases/cerebrospinal fluid , Central Nervous System Diseases/pathology , Encephalitis/cerebrospinal fluid , Feline Infectious Peritonitis/cerebrospinal fluid , Feline Infectious Peritonitis/pathology , Female , Granuloma/cerebrospinal fluid , Granuloma/veterinary , Male , Meningococcal Infections/cerebrospinal fluid , Meningococcal Infections/veterinary , Neoplasms/cerebrospinal fluid , Neoplasms/veterinary , Retrospective Studies , Spinal Cord Neoplasms/cerebrospinal fluid , Spinal Cord Neoplasms/veterinary , Thiamine Deficiency/cerebrospinal fluid , Thiamine Deficiency/veterinary , Toxoplasmosis, Animal/cerebrospinal fluid , Toxoplasmosis, Animal/pathology
11.
Am J Vet Res ; 62(6): 934-7, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11400853

ABSTRACT

OBJECTIVE: To assess selenium (Se) status of cats in 4 regions of the world and to compare results for Se status with reported incidence of hyperthyroidism in cats in those regions. ANIMALS: 50 cats (30 from 2 regions with an allegedly high incidence of hyperthyroidism and 20 from 2 regions in which the disease is less commonly reported). PROCEDURE: Hematologic samples (heparinized whole blood, plasma, and RBC fractions) were obtained from 43 healthy euthyroid cats and 7 hyperthyroid cats. Plasma concentration of Se and activity of glutathione peroxidase (GPX) in whole blood and plasma were determined. RESULTS: Plasma concentration of Se and GPX activity in whole blood or plasma did not differ significantly among cats from the 4 regions. However, cats had a plasma concentration of Se that was approximately 5 times the concentration reported in rats and humans. The GPX activity in whole blood or plasma in cats generally was higher than values reported in rats or humans. CONCLUSIONS AND CLINICAL RELEVANCE: Cats have higher Se concentrations in plasma, compared with values for other species. However, Se status alone does not appear to affect the incidence of hyperthyroidism in cats. High Se concentrations may have implications for health of cats if such concentrations are influenced by the amount of that micronutrient included in diets.


Subject(s)
Cat Diseases/metabolism , Hyperthyroidism/veterinary , Selenium/metabolism , Animals , Cat Diseases/epidemiology , Cats , Denmark/epidemiology , Female , Glutathione Peroxidase/blood , Hyperthyroidism/epidemiology , Hyperthyroidism/metabolism , Male , Queensland/epidemiology , Scotland/epidemiology , Selenium/blood , Statistics, Nonparametric , Thyroxine/blood , Western Australia/epidemiology
12.
J Clin Psychopharmacol ; 21(1): 78-84, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11199952

ABSTRACT

Although methadone maintenance is designed to stabilize opioid-dependent patients, some experience significant withdrawal in the latter part of the 24-hour interdosing interval. This study was designed to determine the mood changes that maybe associated with such withdrawal. Eighteen methadone patients, nine of whom experienced significant withdrawal, were tested over a single interdosing interval. During this time, 13 blood samples were collected to measure plasma racemic methadone concentrations, and the Profile of Mood States (POMS) was administered on 11 of these occasions. The POMS was also administered on 11 occasions over 24 hours to 10 drug-free healthy controls. In comparison with controls, methadone patients showed increased anger, depression, tension, confusion, and fatigue, as well as decreased vigor. For all scales, maximal differences from controls occurred at times of trough methadone concentration and minimal differences around the time of peak concentration. Changes in mood over the interdosing interval were more exaggerated in the nine patients who experienced significant withdrawal compared with those who did not. The composite Total Mood Disturbance (TMD) scores were calculated for each subject at each time point. The sigmoid Emax model was used to relate plasma concentrations to these data and to calculate the slope factor (N). This model could be fitted for 14 of the 18 patients with a mean +/- SEM slope factor of 2.2 +/- 0.5. TMD score was also shown to be inversely related to the rate of decline in methadone concentration from peak to trough. These results show that significant mood changes occur in response to changes in methadone concentration, and these are more pronounced in those who experience withdrawal. The concentration-effect relationships suggest that relatively small changes in plasma concentration will result in significant mood change. Differences in the degree of mood change between those who do and do not experience significant withdrawal may be explained by variation in the rate of decline in plasma concentration from peak to trough.


Subject(s)
Affect/drug effects , Analgesics, Opioid/pharmacology , Methadone/pharmacology , Opioid-Related Disorders/drug therapy , Adult , Analgesics, Opioid/blood , Female , Humans , Male , Methadone/blood , Middle Aged , Opioid-Related Disorders/blood , Opioid-Related Disorders/physiopathology , Substance Withdrawal Syndrome/drug therapy , Substance Withdrawal Syndrome/psychology
13.
Br J Clin Pharmacol ; 50(5): 427-40, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11069437

ABSTRACT

AIMS: To investigate the steady-state pharmacokinetics of (R)- and (S)-methadone in a methadone maintenance population. METHODS: Eighteen patients recruited from a public methadone maintenance program underwent an interdosing interval pharmacokinetic study. Plasma and urine samples were collected and analysed for methadone and its major metabolite (EDDP) using stereoselective h.p.l.c. Methadone plasma protein binding was examined using ultrafiltration, and plasma alpha1-acid glycoprotein concentrations were quantified by radial immunoassay. RESULTS: (R)-methadone had a significantly (P < 0.05) greater unbound fraction (mean 173%) and total renal clearance (182%) compared with (S)-methadone, while maximum measured plasma concentrations (83%) and apparent partial clearance of methadone to EDDP (76%) were significantly (P < 0.001) lower. When protein binding was considered (R)-methadone plasma clearance of the unbound fraction (59%) and apparent partial intrinsic clearance to EDDP (44%) were significantly (P < 0.01) lower than for (S)-methadone, while AUCtau_¿u¿ss (167%) was significantly (P < 0. 001) greater. There were no significant (P > 0.2) differences between the methadone enantiomers for AUCtauss, steady-state plasma clearance, trough plasma concentrations and unbound renal clearance. Patients excreted significantly (P < 0.0001) more (R)-methadone and (S)-EDDP than the corresponding enantiomers. Considerable interindividual variability was observed for the pharmacokinetic parameters, with coefficients of variation of up to 70%. CONCLUSIONS: Steady-state pharmacokinetics of unbound methadone are stereoselective, and there is large interindividual variability consistent with CYP3A4 mediated metabolism to the major metabolite EDDP; the variability did not obscure a significant dose-plasma concentration relationship. Stereoselective differences in the pharmacokinetics of methadone may have important implications for pharmacokinetic-pharmacodynamic modelling but is unlikely to be important for therapeutic drug monitoring of methadone, in the setting of opioid dependence.


Subject(s)
Methadone/pharmacokinetics , Narcotics/pharmacokinetics , Adult , Area Under Curve , Female , Humans , Individuality , Kidney/metabolism , Linear Models , Male , Methadone/blood , Methadone/urine , Middle Aged , Narcotics/blood , Narcotics/urine , Orosomucoid/metabolism , Protein Binding , Pyrrolidines/blood , Pyrrolidines/urine , Stereoisomerism , Substance-Related Disorders/blood , Substance-Related Disorders/rehabilitation , Substance-Related Disorders/urine , Substrate Specificity
14.
J Chromatogr B Biomed Sci Appl ; 744(1): 165-76, 2000 Jul 07.
Article in English | MEDLINE | ID: mdl-10985578

ABSTRACT

A stereoselective HPLC assay was developed for the quantification of the enantiomers of methadone and its major oxidative metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in human urine. The compounds were quantified in a single assay following liquid-liquid extraction and stereoselective HPLC with UV detection. Calibration curve concentrations ranged from 0.125 to 12.5 microM for each enantiomer. Assay performance was assessed using quality control samples, and the inter- and intra-assay bias (<10%) and precision (<15%) were acceptable for all compounds. The assay was successfully used to quantitate the enantiomers of methadone and EDDP in urine samples obtained from subjects receiving methadone maintenance therapy.


Subject(s)
Chromatography, High Pressure Liquid/methods , Methadone/urine , Pyrrolidines/urine , Adult , Calibration , Female , Humans , Male , Methadone/analysis , Methadone/metabolism , Middle Aged , Pyrrolidines/analysis , Quality Control , Reference Standards , Stereoisomerism
15.
Hippocampus ; 10(1): 1-16, 2000.
Article in English | MEDLINE | ID: mdl-10706212

ABSTRACT

This paper presents a model of how hippocampal place cells might be used for spatial navigation in two watermaze tasks: the standard reference memory task and a delayed matching-to-place task. In the reference memory task, the escape platform occupies a single location and rats gradually learn relatively direct paths to the goal over the course of days, in each of which they perform a fixed number of trials. In the delayed matching-to-place task, the escape platform occupies a novel location on each day, and rats gradually acquire one-trial learning, i.e., direct paths on the second trial of each day. The model uses a local, incremental, and statistically efficient connectionist algorithm called temporal difference learning in two distinct components. The first is a reinforcement-based "actor-critic" network that is a general model of classical and instrumental conditioning. In this case, it is applied to navigation, using place cells to provide information about state. By itself, the actor-critic can learn the reference memory task, but this learning is inflexible to changes to the platform location. We argue that one-trial learning in the delayed matching-to-place task demands a goal-independent representation of space. This is provided by the second component of the model: a network that uses temporal difference learning and self-motion information to acquire consistent spatial coordinates in the environment. Each component of the model is necessary at a different stage of the task; the actor-critic provides a way of transferring control to the component that performs best. The model successfully captures gradual acquisition in both tasks, and, in particular, the ultimate development of one-trial learning in the delayed matching-to-place task. Place cells report a form of stable, allocentric information that is well-suited to the various kinds of learning in the model.


Subject(s)
Computer Simulation , Hippocampus/physiology , Models, Neurological , Space Perception/physiology , Animals , Behavior, Animal/physiology , Conditioning, Psychological/physiology , Locomotion/physiology , Maze Learning/physiology , Memory/physiology , Rats , Reward
16.
Res Vet Sci ; 68(1): 89-94, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10684764

ABSTRACT

The concentration of serum alkaline phosphatase (SALP) is commonly elevated in hyperthyroid cats. Agarose gel electrophoresis, in tris -barbital-sodium barbital buffer, with and without the separation enhancer neuraminidase, was used to investigate the sources of the constituent isoenzymes of SALP in serum samples from 34 hyperthyroid cats, comparing them to sera from five healthy cats and to tissue homogenates from liver, kidney, bone and duodenum. Contrary to previous reports, treatment of serum with neuraminidase made differentiation of the various isoenzymes more difficult to achieve. A single band corresponding to the liver isoenzyme (LALP) was found in 100 per cent of healthy cats. Eighty-eight per cent of the hyperthyroid cats showed two bands, corresponding to the liver and bone (BALP) isoenzymes while 12 per cent showed a LALP band alone. In hyperthyroid cats, there was a significant correlation between the serum L-thyroxine concentrations and the SALP concentrations. These findings suggest pathological changes in both bone and liver in most cases of feline thyrotoxicosis.


Subject(s)
Alkaline Phosphatase/blood , Cat Diseases/blood , Hyperthyroidism/blood , Animals , Bone and Bones/enzymology , Cat Diseases/enzymology , Cats , Female , Hyperthyroidism/enzymology , Hysterectomy , Intestines/enzymology , Isoenzymes/blood , Kidney/enzymology , Liver/enzymology , Male , Orchiectomy , Ovariectomy , Reference Values
17.
J Mol Endocrinol ; 24(1): 119-26, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10657003

ABSTRACT

We have investigated thyroid hormone deiodination in the liver, kidney and thyroid of the domestic cat. Affinity labelling with (125)I-bromoacetyl reverse T(3) (125)(I-BrAc-rT(3) demonstrated that liver and kidney, but not the thyroid, express type I iodothyronine deiodinase (IDI), results that were confirmed by measuring the activity of the IDI using (125)I-rT(3) and T(4) as substrate. Feline hepatic and renal IDI metabolised rT(3) at approximately 0.2% of the rate of rat hepatic IDI under identical assay conditions. The K(m) of the feline enzyme was at least 500-fold greater than that of rat IDI. However, feline and rat hepatic IDI metabolised T(4) at a similar rate and had similar K(m) values (1.35 microM and 2.25 microM, respectively). This study demonstrates that cats and rats express IDI in the liver and kidney in similar concentrations; however, the feline enzyme appears unable to utilise rT(3) as a substrate under physiological conditions.


Subject(s)
Iodide Peroxidase/metabolism , Iodine/metabolism , Thyroxine/metabolism , Triiodothyronine/metabolism , Affinity Labels , Animals , Cats , Kinetics , Substrate Specificity
18.
J Small Anim Pract ; 40(7): 307-15, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10444749

ABSTRACT

A prospective study was carried out using a combination of propranolol and potassium iodate to assess whether there were beneficial effects in preparing hyperthyroid cats for surgical thyroidectomy. Group A (n = 11) received propranolol from days 1 to 10, followed by propranolol and potassium iodate from days 11 to 20; group B (n = 10) received the reverse regimen. Blood samples were taken daily for subsequent determination of serum total L-thyroxine (TT4), L-triiodothyronine (TT3) and reverse T3 (rT3) concentrations. The signs of hyperthyroidism improved in all cats over the treatment period. At surgery, 36 per cent of the cats in group A had reference range serum TT4 concentrations, while 89 per cent with initially elevated TT3 concentrations had reference range concentrations. In group B, 10 per cent of the cats had reference range TT4 concentrations, while 75 per cent with initially elevated TT3 concentrations had reference range concentrations. The drug regimen used in group A was better tolerated and more effective and offers an alternative before thyroidectomy in cats that cannot tolerate carbimazole.


Subject(s)
Cat Diseases/drug therapy , Hyperthyroidism/veterinary , Potassium Iodide/therapeutic use , Propranolol/therapeutic use , Sympatholytics/therapeutic use , Thyroidectomy/veterinary , Animals , Cat Diseases/surgery , Cats , Drug Administration Schedule , Female , Hyperthyroidism/drug therapy , Hyperthyroidism/surgery , Liver/drug effects , Liver/pathology , Male , Preoperative Care/veterinary , Prospective Studies , Reference Values , Thyroid Gland/drug effects , Thyroxine/blood , Triiodothyronine/blood , Triiodothyronine, Reverse/blood
19.
Clin Pharmacol Ther ; 65(6): 685-94, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10391674

ABSTRACT

OBJECTIVE: To determine plasma racemic methadone concentration-effect relationships for subjective and objective responses and whether pharmacokinetic and/or pharmacodynamic factors influence withdrawal severity. METHODS: Eighteen patients enrolled in a public methadone maintenance program, nine of whom experienced significant withdrawal, received constant doses of methadone once daily for at least 2 months. During an interdosing interval, 13 blood samples were collected to measure plasma racemic methadone concentrations (patients); subjective (withdrawal severity, direct opioid effects, and pain threshold) and objective (pupil diameter and respiratory rate) opioid effects were quantified on 11 occasions (all participants). The sigmoid Emax model was used to relate plasma concentrations and effects and to calculate the slope factor (N). The rate of decline in plasma concentration during each hour from the peak to the trough concentration was calculated. RESULTS: There was an inverse relationship between plasma concentrations and withdrawal severity and pupil diameter, as well as a direct relationship with subjective opioid effects and pain threshold. The mean N values were 5.4+/-0.9 for withdrawal severity, 5.1+/-1.1 for subjective opioid effects, 1.2+/-0.1 for pupil diameter, and 2.8+/-0.7 for pain threshold. Withdrawal severity correlated with the maximum rate of decrease in plasma concentration (P < .01). There were no differences between those who reported significant withdrawal and those who did not with respect to mean area under the plasma concentration versus time curve and predose plasma concentration, but maximal rate of decline was greater in the former group (74.5 versus 42.1 ng/mL/h). CONCLUSIONS: In this group of long-term methadone-maintained recipients, opioid responses were strongly correlated with changes in plasma racemic methadone concentrations. For the subjective responses, notably withdrawal, small changes in plasma concentrations translate into relatively large changes in effect; therefore, clinically important withdrawal is a consequence of more rapid decline in methadone concentration.


Subject(s)
Methadone/pharmacokinetics , Narcotics/pharmacokinetics , Substance Withdrawal Syndrome/blood , Adult , Dose-Response Relationship, Drug , Female , Humans , Male , Methadone/blood , Methadone/therapeutic use , Middle Aged , Narcotics/blood , Narcotics/therapeutic use , Pain Threshold/drug effects , Pupil/drug effects , Respiration/drug effects , Severity of Illness Index , Substance Withdrawal Syndrome/etiology , Substance Withdrawal Syndrome/physiopathology , Time Factors
20.
Br J Clin Pharmacol ; 47(4): 403-12, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10233205

ABSTRACT

AIMS: To investigate the kinetics of CYP-mediated N-demethylation of methadone in human liver microsomes, and examine the role of stereoselectivity and CYP isoforms involved. METHODS: The kinetics of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) formation via N-demethylation of rac-, (R)- and (S)-methadone in human liver microsomes prepared from six liver samples were determined by h.p.l.c., and inhibition of metabolic function was studied using isoform-specific chemical inhibitors and monoclonal antibodies. Microsomes containing expressed CYP3A4, CYP2D6 and CYP2C19 were also used to examine the formation of EDDP. RESULTS: The V max, Km, and CLint values for the formation of EDDP from rac-, (R)- and (S)-methadone were in the ranges of 20-77 nmol mg-1 protein h-1, 125-252 microm, and 91-494 ml h-1 g-1 protein. Km and CLint values for (R)- and (S)-methadone were not statistically significantly different (P >0.05), while V max values for (S)-methadone were 15% (P=0.045) lower than for (R)-methadone. Expressed CYP3A4 and CYP2C19 showed similar reaction rates for both (R)- and (S)-methadone, while CYP2D6 did not catalyse this reaction. Selective chemical inhibitors of CYP3A (troleandomycin, ketoconazole) and monoclonal human CYP3A4 antibodies significantly inhibited (P<0.05) the formation of EDDP in a concentration dependent manner by up to 80%. Sulphaphenazole (CYP2C9) also significantly inhibited (P<0.05) EDDP formation (range 14-25%). There were no statistically significant differences in the inhibition observed between the three substrates. Selective inhibitors of CYP1A2 (furafylline), CYP2A6 (coumarin), CYP2C19 ((S)-mephenytoin), CYP2D6 (quinidine) and CYP2E1 (diethyldithiocarbamic acid sodium salt and monoclonal human CYP2E1 antibodies) had no significant (P >0.05) effect. CONCLUSIONS: The N-demethylation of methadone in human liver microsomes is not markedly stereoselective, and is mediated mainly by CYP3A4 with the possible involvement of CYP2C9 and CYP2C19. Thus, the large interindividual variation reported for methadone pharmacokinetics may be due to variability in the expression of these CYP isoforms, and the reported stereoselectivity in the systemic clearance of methadone in vivo is not due to stereoselectivity in N-demethylation.


Subject(s)
Cytochrome P-450 Enzyme System/physiology , Methadone/metabolism , Microsomes, Liver/metabolism , Mixed Function Oxygenases/physiology , Narcotics/metabolism , Adult , Aged , Cytochrome P-450 CYP3A , Dealkylation , Female , Humans , Middle Aged , Stereoisomerism
SELECTION OF CITATIONS
SEARCH DETAIL
...